Nuvalent, Inc. announced that Henry Pelish, Ph.D., has been promoted to Chief Scientific Officer. In this role, Dr. Pelish will continue to oversee discovery and early-stage development activities. Dr. Pelish contributed to the creation of Nuvalent and joined as Biology lead in 2018, overseeing the discovery and early-stage development of zidesamtinib, NVL-655 and NVL-330 and ongoing research and discovery efforts.

Dr. Pelish earned his Ph.D. in chemistry from Harvard University and has over 15 years of experience in cancer biology, chemical biology and organic chemistry.